- Home
- GECC vs PBYI Comparison
GECC vs PBYI Comparison
Compare GECC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- PBYI
- Stock Information
- Founded
- GECC 2016
- PBYI 2010
- Country
- GECC United States
- PBYI United States
- Employees
- GECC N/A
- PBYI N/A
- Industry
- GECC Finance: Consumer Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- GECC Finance
- PBYI Health Care
- Exchange
- GECC Nasdaq
- PBYI Nasdaq
- Market Cap
- GECC 116.9M
- PBYI 138.4M
- IPO Year
- GECC N/A
- PBYI N/A
- Fundamental
- Price
- GECC $10.85
- PBYI $2.91
- Analyst Decision
- GECC
- PBYI Strong Buy
- Analyst Count
- GECC 0
- PBYI 1
- Target Price
- GECC N/A
- PBYI $7.00
- AVG Volume (30 Days)
- GECC 23.9K
- PBYI 280.0K
- Earning Date
- GECC 05-05-2025
- PBYI 05-08-2025
- Dividend Yield
- GECC 13.55%
- PBYI N/A
- EPS Growth
- GECC N/A
- PBYI 143.51
- EPS
- GECC 0.42
- PBYI 0.77
- Revenue
- GECC $42,909,000.00
- PBYI $232,668,000.00
- Revenue This Year
- GECC $14.33
- PBYI N/A
- Revenue Next Year
- GECC N/A
- PBYI N/A
- P/E Ratio
- GECC $25.73
- PBYI $3.78
- Revenue Growth
- GECC 18.13
- PBYI 2.67
- 52 Week Low
- GECC $8.87
- PBYI $2.23
- 52 Week High
- GECC $11.39
- PBYI $5.20
- Technical
- Relative Strength Index (RSI)
- GECC 67.15
- PBYI 44.50
- Support Level
- GECC $10.47
- PBYI $2.88
- Resistance Level
- GECC $10.25
- PBYI $3.14
- Average True Range (ATR)
- GECC 0.27
- PBYI 0.16
- MACD
- GECC 0.11
- PBYI 0.00
- Stochastic Oscillator
- GECC 91.31
- PBYI 11.36
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.